Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan
Status:
Completed
Trial end date:
2017-04-11
Target enrollment:
Participant gender:
Summary
This study will be conducted in a single center, open-label study with a single group fixed
sequence design to evaluate the effect of repeated oral administration of 600 mg
RIF(Rifampicin) given once daily over 11 days on the single oral dose pharmacokinetics of
VPR(Vilaprisan) and on MDZ(Midazolam) as a reference (probe) substance.